

Publications auxquelles l'Aretasc a participé en 2013

Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population based model derived from the DOGMEs phase II trial of the Gineco.J.Geriatr Oncol 2013-Jan 4(1):48-57

Specific Adverse Events Predict Survival Benefit in Patients treated with Tamoxifen or Aromatase Inhibitors: An international Tamoxifen Exemestane Adjuvant Multinational Trial Analysis (TEAM) Journal of Clinical Oncology: April 22, 2013

Cancer du sein : quel type de surveillance pour optimiser le suivi ? E. Sebban, JM.Vannetzel : La lettre du Sénologue N°59- Janvier-Mars 2013

6 Months versus 12 Months of adjuvant Trastuzumab for patients with HER 2-positive early breast cancer (PHARE): a randomized phase 3 trial. The Lancet Oncology, 11 june 2013; doi: 10.1016/S1470-2045(13)70225-0

BETH: A Randomized Phase III Study Evaluating Adjuvant Bevacizumab Added to Trastuzumab/Chemotherapy for Treatment of HER2+ Early Breast Cancer TRIO -011 / NSABP B-44-1 / BO20906, San Antonio Breast cancer December 2013. D.Slamon, S.Swain, M.Buyse, M.Martin, C.Geyer, Y-H.Im, T.Pienkowski

LORHA: Efficacy and safety of 1st- line Trastuzumab based treatment, administered for least 3 years, in patients with HER 2- positive metastatic or locally advanced breast cancer- Final results: San Antonio Breast Cancer, December 2013.

The Pernetta trial (SAKK 22/10/ Unicancer UC-0140/1207).A randomized phase II trial of Pertuzumab+ Trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2 positive metastatic breast cancer. San Antonio Breast Cancer Symposium

Publications auxquelles l'Aretasc a participé en 2014

Phase III study of Vinflunine plus Gemcitabine versus Paclitaxel plus Gemcitabine in first –line treatment of anthracycline pretreated advanced breast cancer.
Study Victoria: Abstract Asco 2014.

Nanobitic sélectionnée pour presenter les donnes de l'étude de NBTXR3 lors de la 50 ème conférence Asco: Chicago june 2- 2014 poster

Phase II study of cetuximab pemetrexed, cisplatin and concurrent radiotherapie in patients with locally advanced, unresectable stage III, non-squamous non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial ;abstract discussion session S405, Asco June 1-Chicago 2014.

Hormonothérapie des cancers du sein. Quoi de neuf ? 4 LA LETTRE DU
CHIRURGIEN : GENESIS — N° 181 — Octobre/Novembre 2014 • 11JMVannetzel, JF
Llory, E Sebban.